(Press-News.org) Contact information: Philippe-Gabriel Steg
gabriel.steg@bch.aphp.fr
33-607-246-224
INSERM (Institut national de la santé et de la recherche médicale)
A new treatment for heart attack will soon be available for emergency teams and the emergency ambulance
A new strategy for emergency anticoagulant treatment for patients with acute myocardial infarction has been put in place by a team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at Hôpital Bichat, AP-HP, Université Paris Diderot). These results from the EUROMAX clinical trial are published in The New England Journal of Medicine.
Myocardial infarction, commonly called "heart attack," remains the leading cause of death worldwide, and affects nearly 100,000 individuals a year in France. The reference treatment is urgent dilation of the arteries to enable the blood to circulate to the heart (This medical procedure is known as primary angioplasty). Angioplasty requires injectable anticoagulant treatment for which several options are available.
An international team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at Hôpital Bichat, AP-HP, Université Paris Diderot) has just reported the results of a large international clinical trial carried out in 9 European countries, on nearly 2,200 patients, testing the administration of anticoagulant treatment prior to arrival in hospital by emergency teams and the emergency ambulance service, and comparing the two strategies, in The New England Journal of Medicine . The first is based on heparin (traditional treatment), the other on a more specific anticoagulant, bivalirudin. One of the main drawbacks of these anticoagulant treatments is the risk of associated haemorrhage. "By dilating the arteries, we also thin the blood, with the risk of uncontrolled bleeding if haemorrhage occurs," explains Philippe-Gabriel Steg.
After 30 days of monitoring, bivalirudin reduced the risk of death or serious bleeding by 8.5 to 5.1% and the risk of death, myocardial infarction or major bleed by 9.2 to 6.6%, compared with the strategy using heparin.
This benefit was mainly linked to the reduction in serious bleeding, at the cost of an increased risk of stent thrombosis . "The benefits are robust and consistent for all sub-groups tested, and in particular, consistent regardless of the type of oral anti-clotting treatment or route of arterial access used for angioplasty (via the radial or femoral artery)," explains Philippe-Gabriel Steg.
These results open up the way to using bivalirudin as an anticoagulant at the pre-hospital phase of myocardial infarction in patients being urgently transferred. They represent progress in the treatment of myocardial infarction that can be immediately used.
###
The EUROMAX trial was conducted with the support of The Medicines Company. It is registered in Clinical Trials.gov, under the reference NCT01087723.
Sources
Bivalirudin Started During Emergency Transport for Primary PCI
Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, for the EUROMAX Investigators*
The New England Journal of Medicine 30 October 2013
Investigator contact
Philippe-Gabriel Steg
Inserm Unit 698, "Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling"
Cardiologie, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, France,
E-mail: gabriel.steg@bch.aphp.fr.
Tel.: +33 1 40 25 86 69 //(0)6 07 24 62 24
Attention overseas investigators (San Francisco – 8-hour time difference) to present the trial results at the TCT conference. If you call at 16:00, Paris time, it will be 8:00 for the investigator.
Press contact
presse@inserm.fr
A new treatment for heart attack will soon be available for emergency teams and the emergency ambulance
2013-10-30
ELSE PRESS RELEASES FROM THIS DATE:
Research confirms bottom-feeding behavior of humpback whales
2013-10-30
Research confirms bottom-feeding behavior of humpback whales
DURHAM, N.H. – Humpback whales are known for the complexity of their feeding techniques, which include "trapping" krill and other prey within bubble nets they produce and gulping up to two-thirds ...
Improving earthquake early warning systems for California and Taiwan
2013-10-30
Improving earthquake early warning systems for California and Taiwan
Case studies for Calif. and Taiwan focus on EEWS
SAN FRANCISCO, October 30, 2013 -- Earthquake early warning systems may provide the public with crucial seconds to prepare for severe ...
NASA eyes a 'decoupled' Tropical Depression Raymond
2013-10-30
NASA eyes a 'decoupled' Tropical Depression Raymond
Satellite data shows that the lower level circulation of Raymond decoupled from the middle layer of the storm. When a Tropical Depression decouples, it means the layers of circulation in the atmosphere are no ...
BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy
2013-10-30
BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy
A review article by researchers at Boston University School of Medicine (BUSM) suggests that epigenetics may be a useful target to stop the growth, spread and ...
A sauropod walks into a bar. 'Why the long neck?'
2013-10-30
A sauropod walks into a bar. 'Why the long neck?'
PLOS ONE introduces a new Collection on Sauropod Gigantism
A new PLOS Collection featuring research on the complex evolutionary cascade theory that made the unique gigantism of sauropod dinosaurs possible ...
Rare earths in bacteria
2013-10-30
Rare earths in bacteria
Methane-decomposing bacteria from hot springs need the valuable metals to produce energy
This news release is available in German.
Rare earths are among the most precious raw materials of all. These metals ...
Study finds pre-hospital administration of bivalirudin substantially improves outcomes compared to heparin in heart attack patients
2013-10-30
Study finds pre-hospital administration of bivalirudin substantially improves outcomes compared to heparin in heart attack patients
Results of the EUROMAX trial presented at TCT 2013; findings simultaneously published in the New England Journal of Medicine
SAN FRANCISCO, ...
HPV vaccination rates alarmingly low among young adult women in South
2013-10-30
HPV vaccination rates alarmingly low among young adult women in South
Rates vary by region; indicate need for publicly funded vaccine programs
GALVESTON, Texas -- Initiation and completion rates for the human papillomavirus vaccine series ...
NASA sees Tropical Storm Krosa approach the Philippines
2013-10-30
NASA sees Tropical Storm Krosa approach the Philippines
NASA's Terra and Aqua satellites captured visible and infrared data on intensifying Tropical Storm Krosa as it heads for a landfall in the northern Philippines. Krosa is known as "Vinta" in the Philippines.
Several ...
Results of the TRYTON trial presented at TCT 2013
2013-10-30
Results of the TRYTON trial presented at TCT 2013
Clinical trial finds that a strategy of using of a bare metal stent in the side branch for true bifurcation coronary lesions is safe, but does not meet non-inferiority endpoint compared to provisional stenting
SAN FRANCISCO, ...